A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults
A Phase I Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults
Sponsor: AstraZeneca
Listed as NCT06469151, this PHASE1 trial focuses on Healthy Participants and remains completed. Sponsored by AstraZeneca, it has been updated 14 times since 2024, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Nov 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE1
-
Oct 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE1
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE1
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE1
▶ Show 9 earlier versions
-
May 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE1
-
Mar 2025 — May 2025 [monthly]
Active Not Recruiting PHASE1
-
Feb 2025 — Mar 2025 [monthly]
Active Not Recruiting PHASE1
-
Jan 2025 — Feb 2025 [monthly]
Active Not Recruiting PHASE1
-
Dec 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Oct 2024 — Dec 2024 [monthly]
Recruiting PHASE1
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Jun 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .